China NMPA Drug Inspection - Hubei Changjiangyuan Pharmaceutical Co., Ltd. - Processed Polygonum multiflorum
China NMPA drug inspection for Hubei Changjiangyuan Pharmaceutical Co., Ltd. published April 29, 2020. Drug: Processed Polygonum multiflorum. On April 29, 2020, the Henan Provincial Drug Administration released an announcement identifying 15 batches of substanda
One-time purchase from the GKS catalog. Lifetime access in your library. Single documents and full company profiles available. All sales final.
China NMPA drug inspection for Hubei Changjiangyuan Pharmaceutical Co., Ltd. published April 29, 2020. Drug: Processed Polygonum multiflorum. On April 29, 2020, the Henan Provincial Drug Administration released an announcement identifying 15 batches of substanda
Access our comprehensive regulatory intelligence platform to analyze patterns, track compliance trends, and stay ahead of regulatory changes.
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust GKS for their regulatory compliance needs.
Try KeyPedia Today
Explore our real use cases and discover our features in depth.
Subscribe to our newsletter
Get the latest updates and insights delivered to your inbox